AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01262118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 (tasocitinib)
Description: CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
Study NCT02403284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Subcutaneous injection by patient
Study NCT02403284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Subcutaneous injection daily
Study NCT02032108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counselling
Description: A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress.
Study NCT03702491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur
Description: 3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
Study NCT03514706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: volume controlled ventilation
Description: Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36
Study NCT03514706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pressure controlled ventilation
Description: Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36
Study NCT02108652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
Study NCT04151823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
Study NCT04151823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunofos
Description: Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
Study NCT04151823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Description: Promotion of physical activity will be encouraged at t0, t1, t2
Study NCT04151823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy food habits promotion
Description: Promotion of healthy food habits will be encouraged at t0, t1, t2
Study NCT01182181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole (Teva Pharmaceuticals USA)
Description: 1 mg Tablets
Study NCT01182181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole (Arimidex®)
Description: 1 mg Tablets
Study NCT00812838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 units of Botulinum Toxin Type A
Description: Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
Study NCT00812838 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free normal saline
Description: Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
Study NCT00812838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 units Botulinum Toxin A
Description: Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
Study NCT03758456 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HAL-MRE1
Description: HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
Study NCT03758456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAL-MRE1
Description: HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
Study NCT02610621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy without sentinel node biopsy
Description: Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
Study NCT03762083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pHyph, Gedea pessary
Description: pHyph is a vaginal tablet for the treatment of BV.
Study NCT01534806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac(0.5mg/kg) IV push
Study NCT01534806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% - 10 mL IV push
Study NCT02597036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV
Study NCT03693469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study NCT02597036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02597036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study NCT04237714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smiling is fun
Description: Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador.
Study NCT02767102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine with melatonin
Description: Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
Study NCT02767102 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red wine without melatonin
Description: Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
Study NCT03440983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI data acquiring in healthy volunteers
Description: The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
Study NCT02654613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality Improvement Model of Care
Description: QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context.
Study NCT00799136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: R-EPOCH and cART
Description: This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
Study NCT04057664 — intervention group
Intervention type: BEHAVIORAL
Intervention: Learning of Coping Strategies
Description: Group sessions with psychotherapy and physiotherapy
Study NCT01576913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music listening
Description: Listening to tempo music while cycling in an exercise test
Study NCT00865813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: 1. Instillation of anesthetic eye drops.~2. Asepsis~3. Placement of surgical cloths and drapes~4. Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~5. Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~6. Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade
Study NCT03462498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-months DAPT
Description: 1-month DAPT followed by 59-month monotherapy
Study NCT03462498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month DAPT
Description: 12-month DAPT followed by 48-month monotherapy
Study NCT01022164 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fibrin glue
Study NCT02671825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR0200
Description: PUR0200 dry powder inhalation
Study NCT01046422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 15mg, Active, Daily, 28 days
Study NCT01046422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 50mg, Active, Daily, 28 days
Study NCT01046422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 150mg, Active, Daily, 28 days
Study NCT01046422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Capsule, Oral, 50mg BID, Active, Daily, 28 days
Study NCT01046422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0mg, Daily, 28 days
Study NCT01046422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
Study NCT01046422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
Study NCT02110511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blended lentils
Description: blended lentils burritto breakfast
Study NCT02110511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blended lentils
Description: blended lentils burritto breakfast
Study NCT02110511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: whole lentils
Description: whole lentils breakfast burritto
Study NCT02110511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole lentils
Description: whole lentils breakfast burritto
Study NCT02110511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no lentils
Description: No lentils control breakfast burritto
Study NCT02110511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no lentils
Description: No lentils control breakfast burritto
Study NCT04080063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
Study NCT01009138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific CBT (DS-CBT)
Description: 5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~* Problem Analysis and Definition~* Problem Solving Intervention~* Cognitive Restructuring~* Activation of personal and social Resources~* Goal Definition and Agreement
Study NCT01009138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Education
Description: Standard Diabetes Education Lesson including~* Health Care and specific Topics (e. g. Blood Pressure)~* Social Aspects of Living with Diabetes~* Diabetes Complications~* Sports, Activities and Exercise~* Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~* Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy
Study NCT02974725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: LXH254 will be supplied as tablet for oral use.
Study NCT02974725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: LTT462 will be supplied as hard gelatin capsule for oral use.
Study NCT02974725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be supplied as film-coated tablet for oral use
Study NCT02974725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib will be supplied in tablets and hard gelatin capsules.
Study NCT01650935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
Study NCT02205099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL15508
Study NCT02205099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03536078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home phototherapy
Study NCT02671825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: Dry Powder Inhalation Reference Product
Study NCT01711619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subcutaneous nerve stimulation
Description: subcutaneous nerve stimulation plus optimized medical management
Study NCT01711619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Medical Management
Description: Optimized medical management
Study NCT01711619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Medical Management
Description: Optimized medical management
Study NCT00881907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
Study NCT00796744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NorLeu3-A(1-7) in a gel formulation
Description: Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
Study NCT00796744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NorLeu3-A(1-7) in a gel formulation
Description: Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
Study NCT03104218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS group
Description: Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
Study NCT03104218 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo group
Description: Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition.
Study NCT04504175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes
Study NCT00659776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
Study NCT01759836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Atorvastatin 20mg daily for 1 year
Study NCT01759836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin 20mg daily for 1 year
Study NCT01036659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Description: subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
Study NCT01036659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Description: subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
Study NCT03057964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL (Pulsed Dye Laser)
Description: For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
Study NCT03057964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Photothermolysis Laser
Description: For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
Study NCT03856333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: exercises, physical agents
Study NCT01929954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gintuit
Description: One time placement of Gintuit over socket graft.
Study NCT01929954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Gide
Description: One time placement of Bio-Gide over socket graft.
Study NCT03280225 — intervention group
Intervention type: OTHER
Intervention: External facilitation
Description: Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation.
Study NCT00791830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Tablets, 300 mg \* 1 daily, 1 year
Study NCT00791830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching irbesartan 150 mg
Description: Tablets, 300 mg \* 1 daily, 1 year
Study NCT02816541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvis Retroverted
Description: Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).